Clinical trials: Cetuximab
Colorectal Cancer, Pancreatic Cancer
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0511 in adult participants with solid tumors as monotherapy…
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Solid Tumor
- Trial name
- NCT07300150
- Testing
- PT0511, Cetuximab
- Where
- 9 sites in United States, South Korea
- Volunteers
- 210 people
- Sponsor
- PAQ Therapeutics, Inc.
Advanced Solid Tumors
QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
Phase 1 study to determine the safety, tolerability, and anti-tumor activity of QTX3544 as a single agent or in combination with cetuximab.
- Trial name
- NCT06715124
- Testing
- QTX3544, Cetuximab
- Where
- 10 sites in United States
- Volunteers
- 237 people
- Sponsor
- Quanta Therapeutics
Metastatic Colorectal Cancer
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
The purpose of this study is to learn about the effects of three study medicines (encorafenib, cetuximab, and pembrolizumab) given together for the treatment of colorectal cancer that: is metastatic (spread to other parts of the…
- Trial name
- SEAMARK (NCT05217446)
- Testing
- Encorafenib, Cetuximab, Pembrolizumab
- Where
- 59 sites in United States, Australia and 13 more
- Volunteers
- 108 people
- Sponsor
- Pfizer
Head and Neck Squamous Cell Carcinoma
A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
The primary objective of the study is to evaluate the comparability of efficacy, safety, and immunogenicity of RPH-002 and Erbitux® when administered in combination with docetaxel and cisplatin as first-line therapy in patients…
- Trial name
- NCT07435324
- Testing
- RPH-002, Erbitux®, Cisplatin
- Where
- 34 sites in Russia, Uzbekistan
- Volunteers
- 161 people
- Sponsor
- R-Pharm
Solid Tumors, Melanoma
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of CFT1946 as well as to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of CFT1946 as monotherapy (Arm A) and in…
- Conditions
- Solid Tumors, Melanoma, NSCLC, CRC
- Trial name
- NCT05668585
- Testing
- CFT1946, Trametinib, Cetuximab
- Where
- 26 sites in United States, France and 3 more
- Volunteers
- 89 people
- Sponsor
- C4 Therapeutics, Inc.
Colorectal Cancer
PETACC-8 miR-31-3p and miR-31-5p Ancillary Study
This is a prospective-retrospective study to determine if the expression of the miRNA's miR-31-3p and miR-31-5p are prognostic of patient outcomes or predictive of the benefit from anti-EGFR therapy in stage III Colon Cancer.
- Trial name
- NCT03362684
- Testing
- Cetuximab, FOLFOX
- Volunteers
- 1,808 people
- Sponsor
- IntegraGen SA
Carcinoma, Non-Small-Cell Lung
Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer
The study will enroll approximately 33 EGFr positive chemotherapy-naive stage IV non-small cell lung cancer patients. Patients will receive cetuximab in combination with carboplatin and paclitaxel for two cycles or until disease…
- Trial name
- NCT00034541
- Testing
- cetuximab, paclitaxel, carboplatin
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
Cancer
Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer
This is an open-label, multicenter, ascending multiple dose study of REGN1400 alone and in combination with erlotinib or cetuximab administered to patients with certain types of cancer.
- Trial name
- NCT01727869
- Testing
- REGN1400, Erlotinib, Cetuximab
- Where
- 6 sites in United States
- Volunteers
- 56 people
- Sponsor
- Regeneron Pharmaceuticals
Non-Small-Cell Lung Carcinoma
Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
The primary purpose of this clinical research study is to learn if patients treated with the combination of Taxane/Carboplatin plus Cetuximab (C/T/C) have a longer progression-free survival than patients treated with…
- Trial name
- NCT00112294
- Testing
- Paclitaxel (Taxane), Docetaxel (Taxane), Carboplatin
- Where
- 124 sites in United States
- Volunteers
- 755 people
- Sponsor
- Eli Lilly and Company
Head and Neck Cancer
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
This phase II, open-label, randomized study will evaluate the efficacy and safety of MEHD7945A versus cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck who have progressed during or…
- Trial name
- NCT01577173
- Testing
- MEHD7945A, cetuximab
- Where
- 51 sites in United States, Australia and 9 more
- Volunteers
- 122 people
- Sponsor
- Genentech, Inc.
Neoplasms
Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours
The trial is divided in two parts, Part A and Part B. Part A will involve dose-finding of dose-limiting toxicity (DLT) and MTD in patients with advanced solid tumours.
- Trial name
- NCT02020577
- Testing
- Cetuximab( erbitux®), Afatinib
- Where
- 2 sites in France, Spain
- Volunteers
- 58 people
- Sponsor
- Boehringer Ingelheim
Metastatic Colorectal Cancer
A Retrospective Review of Liver Resection Rate in Metastatic Colorectal Cancer Patients Following Downsizing Treatment With Chemotherapy Plus Cetuximab in Normal UK National Health Service Clinical Practice
This study is a multi-centre retrospective observational research study which will be conducted in UK centres with specialised liver surgical services.
- Trial name
- RESECT (NCT01460745)
- Where
- 5 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Solid Tumor
PF-07284892 in Participants With Advanced Solid Tumors
The purpose of this first-in-patient, open label study is to determine the maximum tolerated dose and/or recommended dose for further study of PF-07284892 as a single agent and in combination with lorlatinib, encorafenib and…
- Trial name
- NCT04800822
- Testing
- PF-07284892, lorlatinib, binimetinib
- Where
- 11 sites in United States
- Volunteers
- 53 people
- Sponsor
- Pfizer
Colorectal Cancer
Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer
The purpose of this trial is to determine the safety and efficacy of Zalutumumab alone or in combination with Irinotecan for the treatment of patients with Colorectal Cancer
- Trial name
- GEN206 (NCT00677924)
- Testing
- Zalutumumab
- Where
- 3 sites in Belgium
- Volunteers
- 9 people
- Sponsor
- Genmab
Squamous Cell Carcinoma of the Head and Neck Cancer
EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
The purpose of this study is to determine if EMD 1201081 in combination with cetuximab is more efficient than cetuximab alone to control the cancer.
- Trial name
- NCT01040832
- Testing
- Cetuximab, EMD 1201081
- Where
- 35 sites in United States, Belgium and 6 more
- Volunteers
- 107 people
- Sponsor
- EMD Serono
Oropharyngeal Carcinoma (OPC)
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
The goal of this study is to understand whether CRB-701, a targeted form of chemotherapy called an anti-body drug conjugate, will work as a treatment for oropharyngeal (throat, tonsil) cancer.
- Trial name
- TEMPO-1 (NCT07768189)
- Testing
- CRB-701, capcitabine, Cetuximab (EGFR inhibitor)
- Where
- 111 sites in United States, Austria and 12 more
- Volunteers
- 260 people
- Sponsor
- Corbus Pharmaceuticals Inc.
Metastatic Colorectal Cancer
A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer
This is an open-label, parallel designed study to assess the pharmacokinetics, safety and tolerability of the single-dose and multi-dose of a recombinant anti-EGFR monoclonal antibody (CPGJ602) in patients with at least one prior…
- Trial name
- NCT03356158
- Testing
- CPGJ602, Cetuximab
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
- Trial name
- MOONRAY-01 (NCT06586515)
- Testing
- LY3962673, Cetuximab, Gemcitabine
- Where
- 52 sites in United States, Canada and 7 more
- Volunteers
- 630 people
- Sponsor
- Eli Lilly and Company
Colorectal Neoplasms
A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation
The main purpose of this study is to evaluate how well olomorasib is tolerated and what side effects may occur when combined with other interventions in participants with Kirsten rat sarcoma viral oncogene homolog (KRAS)…
- Trial name
- NCT07814417
- Testing
- Olomorasib, Cetuximab, Oxaliplatin
- Where
- 18 sites in United States, China and 1 more
- Volunteers
- 50 people
- Sponsor
- Eli Lilly and Company
Squamous Cell Carcinoma of the Head and Neck
Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer
The purpose of this study is to test a study drug called patritumab. Patritumab may work when combined with other medications that are approved in the UK for treating Squamous Cell Carcinoma of the Head and Neck (SCCHN), called…
- Trial name
- NCT02350712
- Testing
- Patritumab, Cetuximab, Cisplatin
- Where
- 3 sites in United Kingdom
- Volunteers
- 15 people
- Sponsor
- Daiichi Sankyo